Video

Experts Discuss Common AEs With EGFR TKIs

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects (AEs) with EGFR TKIs.

Zosia Piotrowska, MD, is a clinical researcher and lung cancer medical oncologist, Massachusetts General Hospital Cancer Center. Christine Lovly, MD, is an associate professor of medicine, Division of Hematology-Oncology, an Ingram associate professor of Cancer Research, co-leader, the Translational Research and Interventional Oncology Program, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center. Amanda Cass, PharmD, BCPS, is a clinical pharmacist, the Thoracic Oncology Clinic, Vanderbilt University Medical Center.

Lovly, Piotrowska, and Cass, explain that the inhibition of EGFR wild-type, which is commonly expressed in the skin, mucous membranes, and the gut, can lead to many of the skin toxicities associated with EGFR TKIs.

Moreover, the 3 experts discuss the adverse effects specifically associated with the use of osimertinib (Tagrisso). Osimertinib can lead to nail bed changes, rash, and sun sensitivity. Additionally, it is important to take up-front preventative measures to attempt to mitigate these skin toxicities.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center